8AP Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue GrowthSustained high gross margins (~88%) combined with positive TTM revenue growth indicate the company’s products scale efficiently. This supports long-term gross cash generation as sales expand, improving the odds that rising revenue can eventually cover fixed R&D and SG&A spend.
Commercial Launch ExecutionDemonstrated REMS implementation and early prescriber adoption show durable commercial capabilities. Effective specialty distribution and patient support reduce rollout risk, increasing probability that mitapivat and related launches can translate into a sustained, repeatable revenue base over coming quarters.
Conservative Balance Sheet & LiquidityA cash runway above $1 billion and minimal debt give flexibility to fund development and confirmatory trials without immediate refinancing. This structural liquidity shield reduces near-term solvency risk and allows management to prioritize strategic R&D and launch investments.
Bears Say
Persistent Cash BurnSustained multi-hundred-million dollar negative operating and free cash flow materially raises financing risk absent faster revenue scaling. Over months, continued burn can force dilution, debt raises, or spending cuts that reshape R&D timelines and commercial investment priorities.
Deep Operating Losses & Negative MarginsVery large operating losses indicate expenses far exceed current product revenue, limiting reinvestment capacity and depressing returns on equity. Until revenue materially outpaces fixed and variable costs, profitability and shareholder value creation remain structurally constrained.
Pipeline Setback: Tebapivat In SCDDeciding not to advance tebapivat in sickle cell disease reduces optionality and addressable near-term indications. This worsens pipeline risk and shifts growth reliance to fewer programs, increasing the business sensitivity to upcoming mitapivat regulatory and confirmatory outcomes.
Agios Pharma News
8AP FAQ
What was Agios Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Agios Pharmaceuticals’s market cap?
Agios Pharmaceuticals’s market cap is CHF1.75B.
When is Agios Pharmaceuticals’s upcoming earnings report date?
Agios Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 6 days.
How were Agios Pharmaceuticals’s earnings last quarter?
Agios Pharmaceuticals released its earnings results on Apr 29, 2026. The company reported -$1.38 earnings per share for the quarter, beating the consensus estimate of -$1.472 by $0.092.
Is Agios Pharmaceuticals overvalued?
According to Wall Street analysts Agios Pharmaceuticals’s price is currently Undervalued.
Does Agios Pharmaceuticals pay dividends?
Agios Pharmaceuticals does not currently pay dividends.
What is Agios Pharmaceuticals’s EPS estimate?
Agios Pharmaceuticals’s EPS estimate is -1.35.
How many shares outstanding does Agios Pharmaceuticals have?
Currently, no data Available
What happened to Agios Pharmaceuticals’s price movement after its last earnings report?
Agios Pharmaceuticals reported an EPS of -$1.38 in its last earnings report, beating expectations of -$1.472. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Agios Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:8AP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF31.78 (― Downside)
CHF31.78 (― Downside)
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.82%
Trailing 12-Months
Company Description
Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
8AP Stock 12 Month Forecast
Average Price Target
$31.78
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―